RedHill Biopharma Presents New Data Showing Opaganib Effective for Neuroblastoma

RedHill Biopharma announced the independent presentation of new preclinical data at the 2026 American Association for Cancer Research, or AACR, Annual Meeting, showing positive effects of opaganib as potential add-on therapy in models of neuroblastoma, or NB, and triple-negative breast cancer, or TNBC. The positive NB data, from studies undertaken by Penn State University's Jeremy Hengst, and Apogee Biotechnology funded by the Beat Childhood Cancer Foundation and Four Diamonds, indicate that opaganib may enhance the therapeutic efficacy of the oxaliplatin + doxorubicin, or OXDOX, chemotherapy combination in high-risk NB. The data showed that opaganib directly destabilized n-Myc, a key oncogenic driver of neuroblastoma and other solid tumors, regulating cell proliferation, differentiation, and apoptosis during embryonic development, a critical factor driving poor outcomes. A second poster from the University of Kansas' Colette Worcester describes in vitro model data showing that pre-treatment with opaganib, followed by low-dose diABZI treatment, potentiated the downstream STING-mediated effects and may augment anti-tumor immunity in TNBC, which has the poorest prognosis of the breast cancer subtypes. Neuroblastoma is the most common infancy cancer with ~5,500 global pediatric cases per year in children aged 0-14. It accounts for 10% of childhood cancers and 15% of pediatric cancer-related deaths in the U.S. Opaganib received FDA Orphan Drug and Rare Pediatric Disease designations for the treatment of neuroblastoma, a rare pediatric cancer, with potential for a Rare Pediatric Disease Priority Review Voucher.